Nextremity Solutions received FDA 510(k) clearance to market the InCore™ Lapidus system for fusion of the first tarsometatarsal joint.
InCore Lapidus is a three-part construct intended for internal fixation for First Metatarsocuneiform Arthrodesis. An application is pending for CE Mark approval.
Nextremity Solutions received FDA 510(k) clearance to market the InCore™ Lapidus system for fusion of the first tarsometatarsal joint.
InCore Lapidus is a three-part construct intended for internal fixation for First Metatarsocuneiform Arthrodesis. An application...
Nextremity Solutions received FDA 510(k) clearance to market the InCore™ Lapidus system for fusion of the first tarsometatarsal joint.
InCore Lapidus is a three-part construct intended for internal fixation for First Metatarsocuneiform Arthrodesis. An application is pending for CE Mark approval.
Copy to clipboard 
